Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.44 |
| ▸ | PYGL | P06737 | 12/20 | 0.43 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL740438 | 0.92 | SMYD3 (0.45) | SMYD3PYGLCYP51A1IDO1HRH4 | |
| SCHEMBL743763 | 0.86 | SMYD3 (0.46) | SMYD3PYGLCYP51A1IDO1 | |
| SCHEMBL741757 | 0.86 | SMYD3 (0.46) | SMYD3PYGLCYP51A1IDO1 | |
| SCHEMBL741538 | 0.86 | SMYD3 (0.46) | SMYD3PYGLCYP51A1IDO1HRH4 | |
| SCHEMBL740808 | 0.85 | F10 (0.44) | SMYD3PYGLCYP51A1IDO1HRH4 | |
| SCHEMBL739706 | 0.84 | KMT2A (0.50) | SMYD3PYGLCYP51A1IDO1 | |
| SCHEMBL739377 | 0.84 | F10 (0.44) | SMYD3PYGLCYP51A1IDO1 | |
| SCHEMBL4094101 | 0.75 | F10 (0.50) | SMYD3PYGL | |
| SCHEMBL4275693 | 0.75 | F10 (0.50) | SMYD3PYGL | |
| SCHEMBL10476622 | 0.75 | F10 (0.50) | SMYD3PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2431370-A1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-7935824-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | F2, ECE1, MLLT1 | SMYD3 995/4885PYGL 3056/4885CYP51A1 3335/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | SMYD3 1262/4885PYGL 2722/4885CYP51A1 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.